Cynata Therapeutics Reinstated on ASX
Key points
- Trading suspension lifted after trial results announcement
- Phase 3 Osteoarthritis Trial results pending
- Phase 2 Graft versus Host Disease Trial results pending
- Immediate impact on stock price expected
Full summary
Cynata Therapeutics Limited (ASX: CYP) announced the reinstatement of its securities on the Australian Securities Exchange (ASX) following the suspension. The suspension will be lifted immediately after the company releases announcements regarding the results of the Phase 3 Osteoarthritis Trial and Phase 2 Graft versus Host Disease Trial. This reinstatement follows the completion of the necessary announcements, which are expected to have a significant impact on the company's stock price.
Outlook
Pending the release of the Phase 3 and Phase 2 trial results, Cynata Therapeutics expects to see a significant impact on its stock price.
Summary generated by a large language model. Please interpret with care.